Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuroendocrine System

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Neuroendocrine System. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-000370-30 Sponsor Protocol Number: 20150706 Start Date*: 2015-11-26
    Sponsor Name:Norrlands University Hospital
    Full Title: Diagnosis and follow up of neuroendocrine tumours with 68Ga-DotaToc PET/CT
    Medical condition: Neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004019-36 Sponsor Protocol Number: Protocol 2-55-52030-729 Start Date*: 2008-12-01
    Sponsor Name:IPSEN Research and Development, BEAUFOUR IPSEN PHARMA
    Full Title: Open label extension study of lanreotide Autogel 120 mg in patients with non functioning entero-pancreatic endocrine tumour.
    Medical condition: Non functioning entero-pancreatic tumour
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) SK (Completed) BE (Completed) ES (Completed) PL (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001306-30 Sponsor Protocol Number: PROICM2021-04REL Start Date*: 2021-09-13
    Sponsor Name:Institut Régional du Cancer de Montpellier
    Full Title: A prospective randomized phase II study to assess the schemas of retreatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with new progression of intestinal well-differentiated neuroendocrine ...
    Medical condition: Patients with new progression of intestinal well-differentiated neuroendocrine tumor.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002194-22 Sponsor Protocol Number: A-97-52030-270 Start Date*: 2014-01-14
    Sponsor Name:Ipsen Limited
    Full Title: A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progr...
    Medical condition: Symptoms of Neuro Endocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004904-35 Sponsor Protocol Number: Protocol2-55-52030-726 Start Date*: 2006-08-14
    Sponsor Name:IPSEN PHARMA S.A.S.
    Full Title: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg ...
    Medical condition: Non functioning entero-pancreatic tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Completed) CZ (Completed) GR (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-006118-19 Sponsor Protocol Number: 2020-012-00EU1 Start Date*: 2021-06-29
    Sponsor Name:HUTCHMED Limited
    Full Title: An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe
    Medical condition: Neuroendocrine Tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Ongoing) IT (Ongoing) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-005607-24 Sponsor Protocol Number: 8-79-52030-326 Start Date*: 2015-11-30
    Sponsor Name:Ipsen Innovation
    Full Title: Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having ...
    Medical condition: well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) DK (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002453-11 Sponsor Protocol Number: CFTSp116 Start Date*: 2018-01-19
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-li...
    Medical condition: Poorly differentiated extra-pulmonary neuroendocrine carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000726-66 Sponsor Protocol Number: GETNE1206 Start Date*: 2014-10-08
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)
    Full Title: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by ...
    Medical condition: advanced progressive pNETs
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed) ES (Ongoing) DK (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002513-19 Sponsor Protocol Number: 2011/609-31/1 Start Date*: 2012-10-29
    Sponsor Name:Karolinska University Hospital Solna
    Full Title: 68Ga-DOTATOC-PET/CT for diagnosis of neuroendocrina tumours
    Medical condition: Neuroendocrine tumour
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000614-64 Sponsor Protocol Number: VIRUSNET201401 Start Date*: 2015-12-17
    Sponsor Name:Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University
    Full Title: Study of recombinant adenovirus in patients with neuroendocrine neoplasms; safety and efficacy
    Medical condition: Neuroendocrine neoplasms (NENs) is a heterogeneous group with varying symptoms, tumor biology and treatment response. NENs may occur in any organ, most commonly they are observed in the gastroente...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000267-84 Sponsor Protocol Number: CSOM230B2412 Start Date*: 2013-06-07
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continue...
    Medical condition: Cushing’s disease Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    14.1 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) BE (Ongoing) ES (Completed) GR (Completed) FR (Completed) PL (Completed) PT (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002916-24 Sponsor Protocol Number: T-008 Start Date*: 2010-07-22
    Sponsor Name:Trio Medicines Ltd
    Full Title: A single centre, pilot trial of YF476 in patients with chronic atrophic gastritis, hypergastrinaemia and type I gastric carcinoids
    Medical condition: Type I gastric carcinoids, chronic atrophic gastritis and hypergastrinaemia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10060377 Hypergastrinaemia PT
    14.1 10017947 - Gastrointestinal disorders 10003685 Atrophic gastritis LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017769 Gastric carcinoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001013-16 Sponsor Protocol Number: PRODIGE69 Start Date*: 2020-07-20
    Sponsor Name:CHU DIJON
    Full Title: FOLFIRINOX VERSUS PLATINUM - ETOPOSIDE AS FIRST LINE CHEMOTHERAPY FOR METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY ASSOCIATED WI...
    Medical condition: METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000601-27 Sponsor Protocol Number: MERCURY Start Date*: 2022-09-27
    Sponsor Name:Fondazione GONO
    Full Title: Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial
    Medical condition: The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002260-14 Sponsor Protocol Number: UC-0105/1612 Start Date*: 2017-04-03
    Sponsor Name:UNICANCER
    Full Title: Secured access to pembrolizumab for adult patients with selected rare cancer types.
    Medical condition: Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003370-27 Sponsor Protocol Number: DMFMRI201303 Start Date*: 2014-09-25
    Sponsor Name:Rainer Rupprecht, Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg am Bezirksklinikum
    Full Title: Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome
    Medical condition: Major Depressive Disorder is a chronic stress related disorder characterized by depressed mood and by vegetative and cognitive symptoms. Moreover, genetic, neuroendocrine and neurochemical biomarke...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000779-40 Sponsor Protocol Number: VEG109611 Start Date*: 2008-07-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II Trial of Pazopanib, a Pan Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitor, in Relapsed or Refractory Small Cell Lung Cancer (SCLC)
    Medical condition: Relapsed or Refractory Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002597-44 Sponsor Protocol Number: CFZ004 Start Date*: 2014-02-10
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
    Medical condition: Untreated extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004177-83 Sponsor Protocol Number: 37202 Start Date*: 2011-11-14
    Sponsor Name:Academic Medical Center
    Full Title: Boosting the oxytocin system in acute trauma: The effectiveness of intranasal oxytocin treatments and stimulation of social support on preventing trauma related psychopathology
    Medical condition: Posttraumatic Stress Disorder (PTSD) according to criteria in the DSM-IV
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10036316 Post-traumatic stress disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA